Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Rutgers, The State University of New Jersey
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02303366CT.gov Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 | — | Completed | — | — | — |
NCT00448305CT.gov EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients | — | Completed | — | — | — |
NCT02181101CT.gov Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial | — | Completed | — | — | — |
NCT00110695CT.gov Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluorouracilum (this asset) | Rutgers, The State University of New Jersey | Approved | BB · 67 |
| Adriamycin | Merck Sharp & Dohme LLC | P4 | BB |
| Letrozole | Fujian Cancer Hospital | P4 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Docetaxel | Universitas Airlangga | P4 | BB |
| Tamoxifen | Eli Lilly and Company | P3 | BB |
| Exemestane | Fujian Cancer Hospital | P4 | BB |
| Eribulin Monomethanesulfonate | Fudan University | P4 | BB |
| Palbociclib | Eli Lilly and Company | P4 | BB |
+42 more in the Breast Neoplasm cohort
Other indications for Fluorouracilum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 77 |
| Rectal Cancer | — | P3 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fluorouracilum in Breast Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluorouracilum-breast-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →